| pubmed-article:20438081 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20438081 | lifeskim:mentions | umls-concept:C0444626 | lld:lifeskim |
| pubmed-article:20438081 | lifeskim:mentions | umls-concept:C1456409 | lld:lifeskim |
| pubmed-article:20438081 | lifeskim:mentions | umls-concept:C0013171 | lld:lifeskim |
| pubmed-article:20438081 | lifeskim:mentions | umls-concept:C1566826 | lld:lifeskim |
| pubmed-article:20438081 | lifeskim:mentions | umls-concept:C0121925 | lld:lifeskim |
| pubmed-article:20438081 | lifeskim:mentions | umls-concept:C1676059 | lld:lifeskim |
| pubmed-article:20438081 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:20438081 | pubmed:dateCreated | 2010-5-20 | lld:pubmed |
| pubmed-article:20438081 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:abstractText | Diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitors (NNRTIs) have inherent flexibility, helping to maintain activity against a wide range of resistance mutations. Crystal structures were determined with wild-type and K103N HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278). These structures reveal a similar binding mode for TMC125 and TMC278, whether bound to wild-type or K103N RT. Comparison to previously published structures reveals differences in binding modes for TMC125 and differences in protein conformation for TMC278. | lld:pubmed |
| pubmed-article:20438081 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20438081 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20438081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20438081 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20438081 | pubmed:month | May | lld:pubmed |
| pubmed-article:20438081 | pubmed:issn | 1520-4804 | lld:pubmed |
| pubmed-article:20438081 | pubmed:author | pubmed-author:FccpMM | lld:pubmed |
| pubmed-article:20438081 | pubmed:author | pubmed-author:BirkusGabriel... | lld:pubmed |
| pubmed-article:20438081 | pubmed:author | pubmed-author:MukundSusmith... | lld:pubmed |
| pubmed-article:20438081 | pubmed:author | pubmed-author:LiuXiaohongX | lld:pubmed |
| pubmed-article:20438081 | pubmed:author | pubmed-author:HungMagdelein... | lld:pubmed |
| pubmed-article:20438081 | pubmed:author | pubmed-author:LansdonEric... | lld:pubmed |
| pubmed-article:20438081 | pubmed:author | pubmed-author:BrendzaKather... | lld:pubmed |
| pubmed-article:20438081 | pubmed:author | pubmed-author:WangRuthR | lld:pubmed |
| pubmed-article:20438081 | pubmed:author | pubmed-author:KuttyNilimaN | lld:pubmed |
| pubmed-article:20438081 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20438081 | pubmed:day | 27 | lld:pubmed |
| pubmed-article:20438081 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:20438081 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20438081 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20438081 | pubmed:pagination | 4295-9 | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:meshHeading | pubmed-meshheading:20438081... | lld:pubmed |
| pubmed-article:20438081 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20438081 | pubmed:articleTitle | Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. | lld:pubmed |
| pubmed-article:20438081 | pubmed:affiliation | Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, USA. eric.lansdon@gilead.com | lld:pubmed |
| pubmed-article:20438081 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20438081 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
